Strategies for treating latent multiple-drug resistant tuberculosis: A decision analysis

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Holland, David P ^a   Sanders, Gillian D ^a   Hamilton, Carol D ^a,b   Stout, Jason E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ETHAMBUTOL; ETHIONAMIDE; MOXIFLOXACIN; PYRAZINAMIDE; HETEROCYCLIC COMPOUND; ISONIAZID; QUINOLINE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; DRUG EFFICACY; DRUG SENSITIVITY; MATHEMATICAL MODEL; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STRATEGIC PLANNING; ANIMAL; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG THERAPY; ECONOMICS; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; THEORETICAL MODEL;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; ISONIAZID; MARKOV CHAINS; MICE; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; QUINOLINES; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84855841545     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030194     Document Type: Article

References (49)

1. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, et al. (2006) Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194: 479-485.
2. Fraser A, Paul M, Attamna A, Leibovici L, (2006) Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 10: 19-23.
3. Centers for Disease Control and Prevention (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR RecommRep 49: 1-51.
4. Horn DL, Hewlett D Jr, Alfalla C, Peterson S, Opal SM, (1994) Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. NEnglJMed 330: 1241.
5. Lou HX, Shullo MA, McKaveney TP, (2002) Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy 22: 701-704.
6. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, et al. (1997) Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. ClinInfectDis 24: 1264-1265.
7. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP, (2005) High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. EurRespirJ 26: 462-464.
8. Hu Y, Coates AR, Mitchison DA, (2008) Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. International Journal of Tuberculosis and Lung Disease 12: 69-73.
9. Singh R, Manjunatha U, Boshoff HIM, Ha YH, Niyomrattanakit P, et al. (2008) PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release. Science 322: 1392-1395.
10. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, et al. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49: 2294-2301.
11. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, et al. (2005) Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am J Respir Crit Care Med 172: 1452-1456.
12. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, et al. (2000) Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 283: 1445-1450.
13. Lecoeur HF, Truffot-Pernot C, Grosset JH, (1989) Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140: 1189-1193.
14. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, et al. (2011) Three months of rifapentine and isoniazid for latent tuberculosis infection. NEnglJMed 365: 2155-66.
15. Sonnenberg FA, Beck JR, (1993) Markov Models in Medical Decision Making. Medical Decision Making 13: 322-338.
16. Gross Domestic Product Deflator Inflation Calculator, National Aeronautics and Space Administration website. Available: http://cost.jsc.nasa.gov/inflateGDP.html. Accessed 2009 Dec 10.
17. Comstock GW, (1975) Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol 101: 363-382.
18. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, et al. (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 935-952.
19. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh M-LN, et al. (2004) Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis. Am J Respir Crit Care Med 169: 1103-1109.
20. Burgos M, DeRiemer K, Small Peter M, Hopewell Philip C, Daley Charles L, (2003) Effect of Drug Resistance on the Generation of Secondary Cases of Tuberculosis. The Journal of Infectious Diseases 188: 1878-1884.
21. Salpeter EE, Salpeter SR, (1998) Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol 147: 398-406.
22. Pai M, Zwerling A, Menzies D, (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. AnnInternMed 149: 177-184.
23. Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, et al. (2008) Health State Utilities in Latent and Active Tuberculosis. Value Health 11: 1154-1161.
24. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB, (2006) Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 130: 1712-1717.
25. LoBue PA, Moser KS, (2003) Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168: 443-447.
26. Stevens JP, Daniel TM, (1995) Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis. Chest 108: 712-717.
27. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M, (2002) Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 167: 131-136.
28. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, et al. (2008) Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 177: 348-355.
29. Garcia-Garcia ML, Ponce de Leon A, Jimenez-Corona ME, Jimenez-Corona A, Palacios-Martinez M, et al. (2000) Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 160: 630-636.
30. Li Z, Kelley C, Collins F, Rouse D, Morris S, (1998) Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J Infect Dis 177: 1030-1035.
31. Riley RL, Mills CC, O'Grady F, Sultan LU, Wittstadt F, et al. (1962) Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 85: 511-525.
32. van Soolingen D, Borgdorff MW, de Haas PE, Sebek MM, Veen J, et al. (1999) Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 180: 726-736.
33. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO, (1985) Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 132: 125-132.
34. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, et al. (2000) Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117: 744-751.
35. Senneville E, Poissy J, Legout L, Dehecq C, Loiez C, et al. (2007) Safety of prolonged high-dose levofloxacin therapy for bone infections. J Chemother 19: 688-693.
36. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK, (2009) Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects. Antimicrobial Agents and Chemotherapy 53: 3720-3725.
37. Sacks LV, Pendle S, (1998) Factors related to in-hospital deaths in patients with tuberculosis. Archives of Internal Medicine 158: 1916-1922.
38. Arias E, (2007) United States life tables, 2004. NatlVital StatRep 56: 1-39.
39. Salpeter SR, Sanders GD, Salpeter EE, Owens DK, (1997) Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 127: 1051-1061.
40. Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, et al. (2000) Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 4: 931-939.
41. Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR, (1997) A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 112: 63-70.
42. Rajbhandary SS, Marks SM, Bock NN, (2004) Costs of patients hospitalized for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease 8: 1012-1016.
43. Snyder DC, Chin DP, (1999) Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. Am J Respir Crit Care Med 160: 582-586.
44. Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, et al. (1995) Health-care expenditures for tuberculosis in the United States. Arch Intern Med 155: 1595-1600.
45. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, et al. (2009) Fluoroquinolone Resistance in Mycobacterium tuberculosis: The Effect of Duration and Timing of Fluoroquinolone Exposure. Am J Respir Crit Care Med 180: 365-370.
46. Huang T-S, Kunin CM, Shin-Jung Lee S, Chen Y-S, Tu H-Z, et al. (2005) Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 56: 1058-1062.
47. Xu P, Li X, Zhao M, Gui X, DeRiemer K, et al. (2009) Prevalence of Fluoroquinolone Resistance among Tuberculosis Patients in Shanghai, China. Antimicrob Agents Chemother 53: 3170-3172.
48. Holland DP, Sanders GD, Hamilton CD, Stout JE, (2009) Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 179: 1055-1060.
49. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, et al. (2011) 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. The Lancet 377: 1588-1598.